there is a need for large-scale population production methods that need to be optimized for therapies. We know EVs are heterogenous, and EV quality will depend on the quality of the cells, the quality of the media, and the conditions of cell culture. This all need...
Many of today’s blockbuster drugs are delivered via injection, which can be expensive and inconvenient, as well as posing compliance challenges. The race is on to develop an oral delivery method for biologics, eliminating the need for injections.
To identify the factors responsible for restoring the proliferative capacity of mid-old cells, we analyzed the composition of CM from young fibroblasts, including lipids, metabolites, proteins, and long non-coding RNAs (Lnc-RNAs). None of the detected small molecules were known p53-p21Waf1pathway ...
regulating physiological cellular processes.2 Interestingly, recent studies have discovered that transformed-tumor cells can take advantage of these endogenous 'trafficking systems' by transferring molecules that activate cancer-related path- ways such as anti-apoptotic, proliferative or other tumorigenic ones...
One of his most recent accomplishments was co-invention of a new approach to preserving therapeutics of virtually any stripe — from both large and small molecules to vaccines and botanicals – in a manner that could hold several therapeutic and cost advantages. The project was born of a collabo...
Unlike their small molecule drug counterparts, they are often complex molecules with secondary, tertiary, and quaternary structures and generally contain side chains with various chemical properties. The disruption of this complexity can lead to loss of function of the drug. Thus, the formulation of ...
This is one of the reasons that the pipelines of many pharmaceutical companies are quite thin; and in contrast the pipeline of biologics is steadily growing. Although it is hard to pin point the reasons for such adverse effects, it is conceivable that small molecules by virtue of their size ...
New molecular entities – conventional small molecules – have a 5.7% chance of moving through all three phases of clinical trials to US Food and Drug Administration approval, while biologics had a 9.1% probability. Vaccines – with 10 times fewer candidates than other biologics – clocked in ...
An alternative route for venting lactate anions from poorly perfused cells may involve gap junctions assembled from connexin proteins.13 These channels couple the cytoplasm of neighbouring cells into a syncytium and establish high- conductance pathways for the passage of small molecules. Since direct ...
One of the biggest bottlenecks in therapeutic development is that a large proportion of the proteins can currently not be targeted by classical small molecules administered orally1. Challenging targets include proteins with flat, featureless surfaces to which small molecules can hardly bind. Even targets...